Learn about TRIO in ~90 Seconds

Why TRIO

CRO Oncology Experts

CRO Oncology Experts

Oncology is not just another indication in our portfolio. It’s the only one, and it’s our specialty. We understand the therapeutic area, the challenges and the complexities associated with expediting cancer clinical trials. That’s why TRIO Operations is supported by a team of global Key Opinion Leaders who provide input on trial design and execution, promote our trials to accelerate enrollment and critically analyze results.

Our Track record of success

Track Record of Success

All of our phase III trials have completed enrollment on time, if not earlier! Four of the registration trials we’ve conducted have led to approval, changing the lives of countless cancer patients worldwide. We have also developed our expertise in early phase trials, including First-In Human (FIH) studies. This has propelled us to become protagonists across the full drug development pathway.

An A-Team partner

An “A-Team” Partnering with You

We have world-class leadership and operation teams whose main goal is to optimize trial start-up and execution—all while maintaining high-quality and effective collaboration with our Sponsors and Investigators. Over the decades, we’ve built a reputation for long-term partnerships with our customers that are based on success and trust.

Investigator Network

Investigator Network

We’re proud of having built a Top Tier Network of over 500 highly experienced, sought-after investigational sites, spanning more than 20 countries and four continents. Our network has been paramount to our successes.

TRIO Key Figures

100%

Phase III trials enrolled on time

4

Practice-changing trials (and counting)

22,000+

Patients enrolled

100%

Database locks on time over the last 2 years

20+

Sponsors that trusted in TRIO as their clinical research partner

3

Global Hubs

Investigator Network
Trio Locations

The Latest From Trio

TRIO is honored to welcome Mark Pegram, MD to the TRIO Breast Cancer Scientific Committee

Dr. Pegram is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford University School of Medicine. He currently serves as the Associate…

Read More >
TRIO ranks among Uruguay’s best workplaces in 2025 as chosen by Great Place to Work

For the third year in a row, the TRIO Latin American hub has ranked among the best workplaces in Uruguay by Great Place to Work®.…

Read More >
US FDA Approves adjuvant ribociclib based on the results from the NATALEE (TRIO033) trial

Link to the News Article.

Read More >
Read All News

Find Out More

Our Sponsors

Sponsors

At TRIO, we work as your partner to deliver quality oncology trials internationally, accelerate your drug development and improve the lives of patients with cancer. Learn how TRIO can support your oncology clinical study.

Doctor holding a patient's hand

Investigators

Since our inception in 1997, TRIO has been at the forefront of clinical cancer research. We have built deep relationships with highly experienced, sought-after Investigators who are pivotal to our success and recognized for their contributions.